Pomide

প্রাপ্তবয়স্ক:

Pregnancy Testing Prior to Administration: Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating Pomalidomide.Recommended Dosage for Multiple Myeloma: The recommended dosage of Pomalidomide is 4 mg once daily orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression. Give Pomalidomide in combination with dexamethasone.Recommended Dosage for Kaposi Sarcoma: The recommended dosage of Pomalidomide is 5 mg once daily taken orally with or without food on Days 1 through 21 of each 28-day cycle until disease progression or unacceptable toxicity. Continue HAART as HIV treatment in patients with AIDS-related Kaposi sarcoma (KS).Dosage Modifications for Hematologic Adverse Reactions-Multiple Myeloma: Dosage Modifications for Hematologic Adverse Reactions: Initiate a new cycle of Pomalidomide in patients with multiple myeloma (MM) when the neutrophil count is at least 500 per mcL and the platelet count is at least 50,000 per mcL.Kaposi Sarcoma: Dosage Modifications for Hematologic Adverse Reactions Initiate a new cycle of Pomalidomide in patients with KS when the neutrophil count is at least 1000 per mcL and the platelet count is at least 75,000 per mcL.Dosage Modifications for Non-Hematologic Adverse Reactions: Permanently discontinue Pomalidomide for angioedema, anaphylaxis, Grade 4 rash, skin exfoliation, bullae, or any other severe dermatologic reaction. For other Grade 3 or 4 toxicities, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion.Dosage Modifications for Strong CYP1A2 Inhibitors: Avoid concomitant use of Pomalidomide with strong CYP1A2 inhibitors. If concomitant use of a strong CYP1A2 inhibitor is unavoidable, reduce Pomalidomide dose to 2 mg.Pediatric Use: The safety and effectiveness of POMALYST have not been established in pediatric patients.